Letter by Levy and Tribouilloy Regarding Article, “Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial”

To the Editor:

We read with great interest the article by Biviano et al., which addressed the impact of atrial fibrillation (AF) on clinical outcome in patients undergoing transcatheter aortic valve replacement. The authors brilliantly showed that for transcatheter aortic valve replacement patients, AF is associated with increased mortality at 30 days and 1 year, and repeat hospitalizations at 1 year. This article contributes to the awareness of the pejorative prognostic value of AF in aortic stenosis (AS). Valvular heart diseases, especially mitral diseases, are well known to be associated with AF, but the prognostic implications of AF in AS has long remained underrated. The prevalence of AF increases with age because AF is associated with a variety of concomitant conditions, including aging, hypertension, heart failure, valvular heart disease, diabetes mellitus, coronary artery disease, or thyroid dysfunction. Such comorbidities are not only causative factors, but also markers of global cardiovascular risk, explaining the increased rates of death, stroke, thromboembolic events, heart failure, left ventricular dysfunction and hospitalization, degraded quality of life, and reduced exercise capacity reported in AF patients. Previous studies from our group showed the negative influence of AF on overall survival in patients with severe AS with low gradient–low ejection fraction. More recently, we reported, in patients with AS with preserved ejection fraction, that AF has a major impact on the risk of death in both medically and surgically managed patients, irrespective of the functional status and the severity of AS. Thus, we think that, beside the risk of thromboembolism, AF is a powerful marker of risk of death in AS. Therefore, particular care in patients with AS should be taken in case of AF, and AF should be considered for clinical decision making. In short, though AF is common in AS, it is not benign.

Disclosures

None.

Franck Levy, MD
Monaco Cardiothoracic Centre
Monaco, MC

Christophe Tribouilloy, MD, PhD
Department of Cardiology
University Hospital Amiens
Amiens, France

INSERM U-1088
Jules Verne University of Picardie
Amiens, France

References


Letter by Levy and Tribouilloy Regarding Article, "Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial"
Franck Levy and Christophe Tribouilloy

Circ Cardiovasc Interv. 2016;9:
doi: 10.1161/CIRCINTERVENTIONS.116.003705

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/9/5/e003705

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org/subscriptions/